New approaches to intravesical chemo-immunotherapy in superficial bladder cancer

Affiliations

Review

A P van der Meijden. Prog Clin Biol Res. 1992.

. 1992:378:95-101.

No abstract available

Similar articles

Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
Hilton WM, Ercole B, Parekh DJ, Sonpavde G, Ghosh R, Svatek RS. Hilton WM, et al. Expert Rev Anticancer Ther. 2011 Jun;11(6):949-57. doi: 10.1586/era.11.69. Expert Rev Anticancer Ther. 2011. PMID: 21707292 Review.
BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.
Boccon-Gibod L. Boccon-Gibod L. Prog Clin Biol Res. 1992;378:55-7. Prog Clin Biol Res. 1992. PMID: 1301586 Review. No abstract available.
BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne FM, van der Meijden AP, Franssen MP. Debruyne FM, et al. Prog Clin Biol Res. 1989;303:435-46. Prog Clin Biol Res. 1989. PMID: 2506556 Clinical Trial. No abstract available.
BCG in the management of superficial bladder cancer.
Guinan P, Richardson C, Hanna M, Rubenstein M. Guinan P, et al. Prog Clin Biol Res. 1989;303:447-53. Prog Clin Biol Res. 1989. PMID: 2675002 Clinical Trial.
Risk-adapted use of intravesical immunotherapy.
Braasch MR, Böhle A, O'Donnell MA. Braasch MR, et al. BJU Int. 2008 Nov;102(9 Pt B):1254-64. doi: 10.1111/j.1464-410X.2008.07968.x. BJU Int. 2008. PMID: 19035890 Review. No abstract available.